Osteopenia Completed Phase 3 Trials for Risedronic acid (DB00884)

Also known as: Osteopaenia / Bone loss

IndicationStatusPhase
DBCOND0015922 (Osteopenia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00386360Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning MethodPrevention
NCT00859703Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast CancerTreatment